Xanomeline oxalate_product_DataBase

Bioactivity	Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease[1].
Target	muscarinic receptor
Invitro	Xanomeline stimulates phosphoinositide (PI) hydrolysis in the A9 L m1 cells[1].Xanomeline inhibits [3H]-pirenzepine ([3H]-PZ) and [3H]-oxotremorine-M ([3H]-OXO-M) binding to rat brain with Kis of 7 and 3 nM, respectively[1].
In Vivo	Xanomeline robustly stimulates in vivo PI hydrolysis and the effect is blocked by muscarinic antagonists, demonstrating mediation by muscarinic receptors. In mice the ED100 for Xanomeline-induced stimulation of [3H]-IP accumulation is 54 μmole/kg in hippocampus. And in rats the ED100 for Xanomeline-induced stimulation of [3H]-IP accumulation is 8.1 μmole/kg in hippocampus[1]. Animal Model:
Name	Xanomeline oxalate
CAS	141064-23-5
Formula	C16H25N3O5S
Molar Mass	371.45
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. F P Bymaster, et al. Xanomeline Compared to Other Muscarinic Agents on Stimulation of Phosphoinositide Hydrolysis in Vivo and Other Cholinomimetic Effects. Brain Res. 1998 Jun 8; 795(1-2):179-90.

PeptideDB